Compounds > desoxycorticosterone
Page last updated: 2024-08-17

desoxycorticosterone and omapatrilat

desoxycorticosterone has been researched along with omapatrilat in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pu, Q; Schiffrin, EL; Touyz, RM1
Atucha, NM; Del Moral, RG; Garcia-Estañ, J; O'Valle, F; Osuna, A; Rodriguez-Gomez, I; Vargas, F; Wangensteen, R1
de Champlain, J; Demeilliers, B; El Midaoui, A; Lamontagne, D; Laplante, MA; Millette, E; Moreau, P; Wu, R1
Elmarakby, AA; Morsing, P; Pollock, DM; Pollock, JS1
Perlini, S1
Amiri, F; Gannon, P; Pu, Q; Schiffrin, EL1
Brown, L; Hoey, A; Loch, D1

Other Studies

7 other study(ies) available for desoxycorticosterone and omapatrilat

ArticleYear
Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Journal of hypertension, 2002, Volume: 20, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Collagen; Desoxycorticosterone; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; Hypertension; Male; Mesenteric Arteries; Myocardium; Neprilysin; Organ Size; Organophosphonates; Pyridines; Rats; Rats, Sprague-Dawley; Sodium Chloride; Systole; Thiazepines; Vascular Resistance

2002
Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats.
    American journal of hypertension, 2003, Volume: 16, Issue:1

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Creatinine; Desoxycorticosterone; Disease Models, Animal; Drinking; Eating; Enzyme Inhibitors; Hypertension, Renal; Kidney; Male; Natriuresis; NG-Nitroarginine Methyl Ester; Potassium; Pyridines; Rats; Rats, Wistar; Sodium; Thiazepines; Urea

2003
Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension.
    Journal of hypertension, 2003, Volume: 21, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiovascular Diseases; Collagen; Coronary Vessels; Desoxycorticosterone; Heart; Hypertension; In Vitro Techniques; Lisinopril; Male; Myocardium; Pyridines; Rats; Rats, Sprague-Dawley; Sodium Chloride; Superoxides; Thiazepines; Vasomotor System

2003
Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
    Vascular pharmacology, 2003, Volume: 40, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Desoxycorticosterone; Drinking; Eating; Enalaprilat; Endothelin Receptor Antagonists; Endothelins; Hypertension; Kidney; Male; Protease Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sodium; Thiazepines

2003
The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule.
    Journal of hypertension, 2005, Volume: 23, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cell Adhesion Molecules; Desoxycorticosterone; Drug Therapy, Combination; Fibrosis; Heart Diseases; Hypertension; Inflammation; Kidney Diseases; Metalloendopeptidases; Neprilysin; Organophosphonates; Pyridines; Rats; Thiazepines

2005
Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
    Journal of hypertension, 2005, Volume: 23, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Cell Adhesion Molecules; Collagen; Desoxycorticosterone; Drug Therapy, Combination; Enalapril; Fibrosis; Heart Diseases; Hypertension; Inflammation; Kidney Diseases; Metalloendopeptidases; Neprilysin; NF-kappa B; Organophosphonates; Pyridines; Rats; Rats, Sprague-Dawley; Thiazepines

2005
Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2006, Volume: 28, Issue:5

    Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Fibrosis; Heart Ventricles; Hypertension; Hypertrophy; Inflammation; Male; Membrane Potentials; Metalloendopeptidases; Myocardial Contraction; Papillary Muscles; Pyridines; Rats; Rats, Wistar; Sodium Chloride, Dietary; Thiazepines; Ventricular Remodeling

2006